

(EUR)	31/12/2025	31/12/2024
Assets		
Fixed assets	23 482,24	30 176,20
III. Tangible fixed assets	20 082,24	26 776,20
B. Plant, machinery and equipment	20 082,24	26 776,20
C. Furniture and vehicles	0,00	0,00
IV. Financial fixed assets	3 400,00	3 400,00
C. Other financial fixed assets	3 400,00	3 400,00
2. Amounts receivable and cash guarantees	3 400,00	3 400,00
Current assets	529 164,68	797 006,59
VII. Amounts receivable within one year	5 000,00	5 000,00
B. Other amounts receivable	5 000,00	5 000,00
IX. Cash at bank and in hand	456 704,82	721 749,14
X. Accruals and deferred income	67 459,86	70 257,45
Total assets	552 646,92	827 182,79
Equity and liabilities		
Equity	509 248,16	719 456,54
III. Reserves	70 082,24	76 776,20
A. Reserves not available	70 082,24	76 776,20
4. Other	70 082,24	76 776,20
IV. Accumulated profits (+)/ losses (-)	439 165,92	642 680,34
Amounts payable	43 398,76	107 726,25
IX. Amounts payable within one year	43 398,76	39 413,22
C. Trade debts	21 692,88	16 444,51
1. Suppliers	21 692,88	16 444,51
E. Taxes, remuneration and social security	21 705,88	22 968,71
1. Taxes	2 269,20	4 413,15
2. Remuneration and social security	19 436,68	18 555,56
X. Accruals and deferred income	0,00	68 313,03
Total liabilities	552 646,92	827 182,79
Profit and loss account		
I. Operating income	904 562,66	865 881,53
A. Turnover	903 243,16	864 726,33
D. Other operating income	1 319,50	1 155,20
II. Operating charges	1 079 422,93	1 081 773,74
A. Goods for resale, raw materials and consumables	716 299,19	748 686,61
1. Purchases	716 299,19	748 686,61

B. Services and other goods	196 968,07	180 971,69
C. Remunerations, social security costs and pensions	159 461,71	143 815,59
D. Amortisations of and other amounts written down on formation expenses, intangible and tangible fixed assets	6 693,96	6 942,63
G. Other operating charges	0,00	1 357,22
III. Operating profit/loss	-174 860,27	-215 892,21
IV. Financial income	9 129,54	24 217,79
A. Income from financial fixed assets	426,99	425,37
C. Other financial income	8 702,55	23 792,42
V. Financial charges	44 477,65	12 045,06
A. Debt charges	571,00	350,20
C. Other financial charges	43 906,65	11 694,86
VI. Profit/loss of the period before taxes	-210 208,38	-203 719,48
IX. Profit/loss of the period	-210 208,38	-203 719,48
X. Transfer from/to untaxed reserves	6 693,96	6 693,96
A. Transfer from untaxed reserves	6 693,96	6 693,96
XI. Profit/loss of the period available for appropriation	-203 514,42	-197 025,52
Appropriation account	0,00	0,00
A. Profit/loss to be appropriated	439 165,92	642 680,34
1. Profit/Loss of the period available for appropriation	-203 514,42	-197 025,52
2. Profits/loss of the preceding period brought forward	642 680,34	839 705,86
D. Profit/loss to be carried forward	439 165,92	642 680,34
1. Profit to be carried forward	-439 165,92	-642 680,34

REVENUE 2025				
INDUSTRY related	Support			
Advanze Pharma	10.000,00 €	1%		
AstraZeneca	70.000,00 €	10%		
BI	135.000,00 €	19%		
BMRN (BIOMARIN)	5.000,00 €	1%		
E-scopics	1.500,00 €	0%		
Echosens	10.000,00 €	1%		
Gilead	90.000,00 €	13%		
Madrigal	55.300,00 €	8%		
Mirum	8.534,22 €	1%		
Novonordisk	135.000,00 €	19%		
Perspectum	60.000,00 €	9%		
Regeneron	21.000,00 €	3%		
Roche	10.000,00 €	1%		
Takeda	48.659,01 €	7%		
VirBio	20.300,00 €	3%		
Wavescience	15.000,00 €	2%		
TOTAL	695.293,23 €	100%	77%	
NON INDUSTRY related				
EU PROJECTS				
ARTEMIS	63.040,10 €	30%		
HL4EU	14.525,00 €	7%		
Liverscreen	332,26 €	0%		
GripOnMASH	8.450,65 €	4%		
THRIVE	32.325,61 €	16%		
Microb-Predict	3.112,00 €	1%		
Liveration	19.887,26 €	10%		
Viromarkers	24.166,67 €	12%		
IPCureB	16.020,00 €	8%		
MEMBERSHIP	- €	0		
OTHER	26.090,38 €	13%		
TOTAL	207.949,93 €	100%	23%	
TOTAL	903.243,16 €			100%